Recent performance snapshot

Veeva Systems (VEEV) has drawn attention after a mixed period for the stock, with the price at $158.86 and returns down over the past week, month, past 3 months and year to date.

Investors are weighing that share performance against the company’s reported US$3.2b in revenue and US$908.9m in net income, along with its current value score of 4 and a reported intrinsic discount of 46.6%.

While the share price has picked up with a 1-day share price return of 1.67%, the stock’s year to date share price return of 27.62% and 1-year total shareholder return of 34.57% indicate that momentum has been fading over a longer stretch, which some investors are weighing against the reported intrinsic discount of 46.6%.

If you are comparing Veeva Systems with other opportunities in health-focused technology, this could be a prompt to scan the wider set of healthcare related AI stocks through the 32 healthcare AI stocks.

With revenue of about US$3.2b, net income of US$908.9m and a reported intrinsic discount of 46.6% alongside weaker recent returns, is Veeva Systems a potential value opportunity, or is the market already pricing in its future growth?

Most Popular Narrative: 39.9% Undervalued

Veeva Systems' most followed narrative points to a fair value of $264.46 per share, compared with the last close of $158.86, with that gap grounded in detailed revenue, margin and valuation assumptions.

The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.

Want to see what kind of revenue path and margin profile has to line up for that valuation to hold? The narrative leans on compound growth, firmer profitability and a richer future earnings multiple that is more often associated with premium software leaders.

The narrative applies a discount rate of 8.01% to those future cash flows and earnings, then backs into a fair value of $264.46 per share, which is well above both the current share price of $158.86 and the consensus analyst price target of $264.46 that sits behind the story.

Result: Fair Value of $264.46 (UNDERVALUED)

However, some investors are watching to see whether slower subscription growth and intense CRM competition could pressure the premium P/E that the narrative relies on.

Next Steps

Given the mix of potential upside and real risks, are you comfortable with how the story lines up with your own expectations for Veeva Systems? Take a closer look at the company’s 3 key rewards

Looking for more investment ideas?

If you stop with just one stock, you may miss opportunities that fit your goals even better, so broaden your watchlist while this research is still fresh.

• Target potential mispricings by scanning our wider set of 49 high quality undervalued stocks that combine quality with attractive entry points.
• Strengthen your focus on stability by checking companies in the 66 resilient stocks with low risk scores that score well on resilience and risk controls.
• Spot future standouts early by reviewing the screener containing 22 high quality undiscovered gems that pair solid fundamentals with lower current visibility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.